biotech
+3
Sep 18, 2026
•
6 min read
A first-in-class SMA approval, a myelin-repair MS trial clears the FDA, and a small ask for caregivers
Sep 11, 2026
Sep 4, 2026
Novartis's MS data, rare disease firsts, and an exciting update from Precedent Therapeutics
Aug 28, 2026
5 min read